Norden Group’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$212K Sell
938
-7
-0.7% -$1.48K 0.02% 626
2026
Q2
$204K Buy
+945
New +$181K 0.02% 670
2024
Q4
– Sell
-2,424
Closed -$470K – 530
2024
Q3
$470K Buy
2,424
+1,397
+136% +$292K 0.06% 328
2024
Q2
$238K Sell
1,027
-413
-29% -$89.8K 0.05% 357
2024
Q1
$311K Buy
1,440
+290
+25% +$67.9K 0.06% 320
2023
Q4
$298K Sell
1,150
-996
-46% -$245K 0.05% 202
2023
Q3
$552K Buy
+2,146
New +$574K 0.18% 122

Other funds holding BIIB

Norden Group's BIIB Position: Q3 2026 in Review

Norden Group reduced its Biogen (BIIB) stake by 0.74% in Q3 2026, selling an estimated $1.48K and leaving 938 shares worth $212K. The position accounts for 0.02% of the portfolio, ranked #626.

Norden Group first reported a position in BIIB in Q3 2023 and has held it in 7 quarters since. The position peaked at $552K in Q3 2023. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Norden Group held 938 shares of Biogen worth $212K as of Q3 2026.
  • Norden Group sold 7 Biogen shares in Q3 2026, an estimated $1.48K.
  • Biogen made up 0.02% of Norden Group's portfolio in Q3 2026, its #626 holding.
  • Norden Group first reported a position in Biogen in Q3 2023 and has held it in 7 quarters since.
  • Norden Group's Biogen position peaked at $552K in Q3 2023.
  • 1,062 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Norden Group's 13F filing for Q3 2026, filed 20 Oct 2026.